Tech Company Financing Transactions
Solid GT Funding Round
Perceptive Advisors, Biogen Idec and Janus Capital participated in a $42.5 million Series B capital raise for Solid GT. The round was announced by the company on 11/5/2015.
Transaction Overview
Company Name
Announced On
11/5/2015
Transaction Type
Venture Equity
Amount
$42,500,000
Round
Series B
Investors
Proceeds Purpose
which the company will use to advance the development of its novel gene therapy platform for Duchenne muscular dystrophy (DMD), a fatal and untreatable condition.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Bdwy.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Solid exists to bridge the gap and advance treatments to patients. Well-capitalized and focused on results, we are purpose-built to identify and develop the most promising approaches to treat and cure DMD.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ilan Ganot
Chief Medical Officer
Jorge Quiroz
VP - Operations
Alvaro Amorrortu
VP - R & D
Carl Morris
Browse more venture capital transactions:
Prev: 11/5/2015: Biscayne Therapeutics venture capital transaction
Next: 11/5/2015: OfferUp venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs